$12M offtake agreement with leading OTC-pharmaceutical
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Xenitra Limited has signed a three-year pharmaceutical procurement agreement with Kangsheng Hong Kong International Trading Limited, which is expected to generate significant sales for the company. This agreement marks a key milestone in Xenitra's OTC pharmaceuticals division, aligning with its three-pillar growth strategy. The partnership provides immediate access to China's healthcare market through an established distribution network, enhancing Xenitra's operational capabilities. The agreement is designed to facilitate the procurement of a substantial minimum value of pharmaceutical products over the contract period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Xenitra
- $1.1m in OPAL-Tokenised Product Sales in First 7 Weeks
- XEN Appointed as Exclusive Biomiq Skincare China Distributor
- Product sales of $500k in first month of OPAL token launch
- $1.25m Raised to Support Next Phase of Growth
- OPAL token launch of EZZ products sells $100k in first week
Later from Xenitra
- $5m Offtake Agreement Expands OTC-Medicine Business
- Xenitra Raises $1.5m to Accelerate High-Margin Sales Growth
- Appendix 4E and Annual Report
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Xenitra into a list and get an email when it puts out news.
Follow Xenitra